Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
NEUTRAL SIGNAL
██.█% Sign up free to reveal

Cullinan Therapeutics, Inc. (CGEM) AI Forecast

Our AI analyzed Cullinan Therapeutics, Inc.. Create a free account and follow it to see the 90-day price prediction.

✓ Free account • ✓ 30-day free trial

$CGEM Neutral Signal Full forecast available
Sign Up Free

Cullinan Therapeutics, Inc. (CGEM) Stock Forecast 2025

Cullinan Therapeutics, Inc. (CGEM) AI Stock Price Forecast & Investment Analysis

Cullinan Therapeutics, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Cullinan Therapeutics, Inc. (CGEM) - Comprehensive Stock Analysis & Investment Research

Deep dive into Cullinan Therapeutics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on July 27, 2026, 2:58 p.m. (UTC)

Cullinan Therapeutics, Inc. Investment Summary

When evaluating whether Cullinan Therapeutics, Inc. (CGEM) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Cullinan Therapeutics, Inc. (CGEM) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $1 billion, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Cullinan Therapeutics, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Cullinan Therapeutics, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Cullinan Therapeutics, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Cullinan Therapeutics, Inc.

Sign Up Free
Corporate Identity

Cullinan Therapeutics, Inc. (Stock Symbol: CGEM) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Cullinan Therapeutics, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Cullinan Therapeutics, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Cullinan Therapeutics, Inc....

Unlock Full Company Profile

Get complete details about Cullinan Therapeutics, Inc.

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Cullinan Therapeutics, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Cullinan Therapeutics, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Cullinan Therapeutics, Inc....

Unlock Financial Analysis

Get complete financial metrics for Cullinan Therapeutics, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Cullinan Therapeutics, Inc.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Cullinan Therapeutics, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Cullinan Therapeutics, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-150 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Financial Strength & Leverage

Current ratio of 10.28 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Cullinan Therapeutics, Inc. (CGEM) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Cullinan Therapeutics, Inc. stock analysis.

Deep dive into Cullinan Therapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Cullinan Therapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Cullinan Therapeutics, Inc.:

P/B Ratio 2.90x
Market Cap $1.06B
Book Value/Share $5.96
FCF/Share $-2.44
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Cullinan Therapeutics, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Cullinan Therapeutics, Inc.: An ROE of -0.1% indicates room for improvement in shareholder value creation.

ROE -0.1%
ROA -0.1%
ROIC 1.5%
Operating Margin 7.2%
Net Margin -0.4%
EBT Margin 7.2%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Cullinan Therapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Cullinan Therapeutics, Inc.: A current ratio of 10.28 indicates strong liquidity.

Current Ratio 10.28x
D/E Ratio 0.10x
Financial Leverage 1.10x
Interest Coverage -1019.0x
Working Capital $326M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Cullinan Therapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Cullinan Therapeutics, Inc.: Free cash flow of $-150M indicates cash challenges that need attention.

Operating Cash Flow -$6M
Free Cash Flow -$150M
Capital Spending -$144M
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Cullinan Therapeutics, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Cullinan Therapeutics, Inc.:

Understanding Financial Statement Data

What these metrics mean: Key figures from Cullinan Therapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Cullinan Therapeutics, Inc.:

Income Statement
Operating Income $5M
R&D Expense $50M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 361%
Cash & Short-term Investments 75%
Total Liabilities 37%
Short-term Debt 33%
Dividend & Shareholder Information
Shares Outstanding 61M
Growth Metrics (YoY)
Net Income Growth -0.4%

Latest Cullinan Therapeutics, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Cullinan Therapeutics, Inc. (CGEM) stock price and investment outlook.

📰 Loading...

Cullinan Therapeutics, Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Cullinan Therapeutics, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ABOS ██% $157M x 1.8x
ABPO ██% $1M x x
ACOG ██% $179M x 3.1x
ADAPY ██% $8M x x
ADMA ██% $1.94B 11.8x 5.0x
ADPT ██% $3.56B x 16.5x
AGEN ██% $238M 3.7x x
AGTX ██% $800K x x
AIM ██% $7M x 3.3x
ALEC ██% $165M x 15.9x
ALGS ██% $29M x 0.9x
ALLO ██% $628M x 2.3x
ALVO ██% $992M x x
AMGN ██% $200.50B 25.7x 21.8x
APGE ██% $10.05B x x
APTOF ██% $4M x x
ARGX ██% $57.22B x x
ARMP ██% $192M x x
ARTV ██% $492M x 5.6x
ATRA ██% $70M x x
ATYR ██% $49M x 0.8x
AURA ██% $745M x 6.9x
AUTL ██% $405M x 3.7x
AVXL ██% $230M x 1.8x
BCAB ██% $6M x x
BCDA ██% $14M x x
BCLI ██% $11M x x
BCRX ██% $2.38B x x
BDTX ██% $105M x 1.0x
BEAM ██% $2.66B x 2.3x
BIIB ██% $29.53B 21.5x 1.6x
BNTX ██% $23.28B x x
CABA ██% $444M x 4.3x
CADL ██% $722M x 5.2x
CCCC ██% $380M x 1.6x
CELZ ██% $5M x 0.9x
CERO ██% $500K x x
CGEM ██% $1.06B x 2.9x
CGEN ██% $221M 3.1x 2.2x
CGON ██% $6.26B x 5.7x
CGTX ██% $86M x 2.9x
CHRS ██% $221M 1.2x 2.8x
CLDI ██% $2M x 0.4x
CLLS ██% $279M x x
CMPX ██% $382M x 2.1x
CPMV ██% $5M x x
CRDF ██% $65M x 1.9x
CRDL ██% $123M x x
CRIS ██% $9M x 0.7x
CRSP ██% $4.58B x 2.5x
CSBR ██% $83M x 19.5x
CVM ██% $21M x 3.0x
DBVT ██% $820M x 5.1x
DNA ██% $489M x 1.1x
DNLI ██% $3.72B x 4.0x
DTIL ██% $189M x 2.5x
DYAI ██% $44M x x
EDIT ██% $419M x 95.0x
ELUT ██% $40M 0.8x 1.8x
ENGN ██% $127M x 0.5x
ENTX ██% $99M x 9.3x
ENZN ██% $59M x 0.3x
ESLA ██% $32M x x
EVAX ██% $25M x x
EXEL ██% $14.12B 16.9x 7.3x
EXOZ ██% $40M x 26.1x
FATE ██% $293M x 1.6x
FDMT ██% $543M x 1.2x
FENC ██% $351M x 9.3x
GILD ██% $162.53B 17.6x 6.9x
GLUE ██% $1.94B x 3.7x
GNTA ██% $80M x 6.4x
GPLB ██% $260K x x
GRML ██% $30M x 0.6x
HALO ██% $9.58B 27.5x 43.6x
HUMA ██% $172M x 14.8x
IBRX ██% $7.75B x x
IKT ██% $366M x 2.2x
IMA ██% $63M x 0.5x
IMCR ██% $1.81B x 4.6x
IMTX ██% $1.25B x x
IMVT ██% $8.03B x 9.4x
INAB ██% $12M x 0.5x
INKT ██% $50M x x
INMB ██% $46M x 2.3x
INTS ██% $11M x 1.1x
IOVA ██% $2.25B x 3.1x
IPSC ██% $391M x 1.5x
IVVD ██% $172M x 0.9x
JATT ██% $88M x 0.4x
JSPR ██% $24M x 7.1x
KLRS ██% $90M x 1.3x
KOD ██% $2.55B x 22.7x
KRYS ██% $9.64B 42.8x 7.6x
KYMR ██% $9.07B x 5.9x
KYTX ██% $441M x 2.3x
LCTX ██% $267M x 5.0x
LENZ ██% $158M x 0.6x
LIFE ██% $1.87B x 32.2x
LIMN ██% $7M x x
LONA ██% $68M x 1.4x
LXEO ██% $349M x 1.5x
MAZE ██% $1.53B x 4.5x
MESO ██% $2.09B x x
MGTX ██% $986M x x
MGX ██% $46M x 0.3x
MOLN ██% $160M x x
MRNA ██% $22.64B x 3.1x
NBIX ██% $17.52B 26.2x 5.1x
NMRA ██% $281M x 4.0x
NVAX ██% $1.29B x x
OCGN ██% $430M x 74.0x
OTLK ██% $247M x x
PALI ██% $338M x 2.7x
PASG ██% $16M x 1.3x
PCVX ██% $8.03B x 2.7x
PHGE ██% $2M x x
PLUR ██% $19M x x
PLX ██% $189M 12.3x 2.8x
PMCB ██% $6M x 0.2x
PRME ██% $536M x 7.0x
PROK ██% $459M x x
PTHS ██% $96M x 2.7x
QGEN ██% $8.99B x 2.4x
QNCX ██% $18M 2.1x 1.1x
REPL ██% $865M x 5.2x
RGEN ██% $7.76B 151.0x 3.7x
RGNX ██% $656M x 31.1x
RLAY ██% $4.14B x 6.5x
RVMD ██% $37.78B x 25.2x
RXRX ██% $1.60B x 1.6x
SABS ██% $274M x 1.2x
SANA ██% $866M x 7.3x
SCLX ██% $52M x x
SCNI ██% $1M x 0.2x
SGMO ██% $29M x x
SGMOQ ██% $27M x x
SLDB ██% $804M x 2.2x
SLXN ██% $3M x 8.7x
SNTI ██% $13M x 5.2x
SRRK ██% $5.89B x 21.4x
SRZN ██% $231M x x
STRO ██% $391M x x
TARA ██% $226M x 1.3x
TARS ██% $2.52B x 7.2x
TCRX ██% $52M x 0.5x
TECH ██% $11.23B 102.5x 5.4x
TECX ██% $594M x 2.6x
TIL ██% $48M x 0.4x
TNYA ██% $168M x 1.6x
TSHA ██% $1.67B x 7.9x
TVGN ██% $18M x x
TWST ██% $5.75B x 12.6x
VACH ██% $541M 80.4x x
VALN ██% $488M x x
VCEL ██% $2.30B 107.1x 6.5x
VIR ██% $1.51B x 1.9x
VIVS ██% $2M x 0.4x
VOR ██% $1.03B x x
VXRT ██% $121M 3.3x 1.3x
VYGR ██% $186M x 1.1x
WINT ██% $340K x x
XFOR ██% $376M x 2.2x
ZEOX ██% $14M x 19.4x
ZIVO ██% $19M x x
ZURA ██% $502M x 2.3x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Cullinan Therapeutics, Inc. Stock Forecast

How accurate are Cullinan Therapeutics, Inc. stock predictions?

Our AI model shows a 34% Spearman correlation coefficient for CGEM predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Cullinan Therapeutics, Inc. stock price forecasts?

Our analysis considers Cullinan Therapeutics, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Cullinan Therapeutics, Inc. a good investment in 2025?

Based on our AI analysis, Cullinan Therapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Cullinan Therapeutics, Inc. forecasts updated?

Cullinan Therapeutics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Cullinan Therapeutics, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...